CliffBio
small molecule

EVOXAC

CEVIMELINE HYDROCHLORIDE

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameEVOXAC
Active ingredientCEVIMELINE HYDROCHLORIDE
Strength30MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 2000
Marketing statusRX

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

EVOXAC patent cliff — loss of exclusivity — | CliffBio